Ask about this productRelated genes to: BCL2L12 Blocking Peptide
- Gene:
- BCL2L12 NIH gene
- Name:
- BCL2 like 12
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-27
- Date modifiied:
- 2016-10-05
Related products to: BCL2L12 Blocking Peptide
Related articles to: BCL2L12 Blocking Peptide
- Environmental pollution, particularly from industrial production and automobile exhaust emissions, is increasingly recognized as a significant factor in the development of various diseases, including glioblastoma (GBM). However, the relationship between environmental exposure and GBM has not been systematically analyzed. In this study, we utilized machine learning techniques to develop three predictive models for GBM diagnosis, recurrence, and prognosis, considering core genes identified through environmental and clinical data. We applied Random Forest, LASSO regression, logistic regression, and Cox regression models, and validated them with independent external datasets. GO and KEGG functional enrichment analyses were also performed to explore the potential underlying mechanisms. Molecular docking was used to examine interactions between key genes and air pollutants. Our results indicated that polycyclic aromatic hydrocarbons, nitrogen oxides, and particulate matter contribute to the onset and progression of GBM by affecting cell proliferation pathways. Using machine learning and molecular docking, we identified several key genes: NFKBIA and BCL2L12 for onset prediction; DKK3, FGFR1, GLIPR1, and TRIM8 for recurrence prediction; and STAT3, NF1, and KDM5A for prognosis prediction. These genes may serve as potential biomarkers for early diagnosis, recurrence monitoring, and prognosis of GBM. This study underscores the importance of environmental gene interactions in GBM, offering valuable insights into clinical diagnosis and treatment strategies. - Source: PubMed
Publication date: 2025/11/14
Pan JunjiaYuan XuanyaoLin HaoshenZhao RuiYang LinHu Chun - Ovarian cancer remains one of the most lethal gynecological malignancies because of late diagnosis, drug resistance, and limited treatment efficacy. This study explored the anti-apoptotic role of BCL2-like protein 12 (BCL2L12) and whether arctigenin induces apoptosis by targeting BCL2L12. - Source: PubMed
Publication date: 2026/06/17
Yang YingCui PengChen WeiyanWang QunJi TianminWang JiaxinZhao JiaoSong Nan - This study aims to reveal the potential mechanism and potential prognostic markers of programmed cell death (PCD) genes associated with 6-acetoxy-anopterine (6-AA) resistance in prostate adenocarcinoma (PRAD). - Source: PubMed
Publication date: 2026/01/31
Cheng JieMao Dongdong - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis and limited treatment options. Synthetic lethality (SL) represents a significant therapeutic strategy that selectively kills cancer cells without affecting normal cells by targeting the synergistic interaction of two genes. The SL strategy offers new avenues for targeted therapy in TNBC. Although challenges remain-such as drug resistance and biomarker selection-advancing research in SL activity holds promise for delivering clinical benefits to patients. - Source: PubMed
Publication date: 2026/02/06
Miao ShichenWang XiaoGu QimingBian ChengyuFan RuiNi QichaoWang YiZhuang Zhigang - Hepatocellular carcinoma (HCC) is a global challenge with a high cancer-related death rate. Although BCL2L12 has been reported to be upregulated in mice with HCC, and its deletion markedly inhibits HCC progression, its specific role and associated tumorigenesis mechanisms in human HCC remain elusive. Differential gene expression analysis was performed using TCGA and GEPIA databases. Survival probability analysis was conducted using the Kaplan-Meier method. Immune checkpoint-related prognosis in HCC and their correlation with BCL2L12 were analyzed. The correlation between BCL2L12 and immune infiltration was investigated using the TIMER database. MEXPRESS and MethSurv were employed to display methylation of BCL2L12 and prognostic value. Upstream ncRNAs of BCL2L12 were predicted using starBase, String and TargetScan. Protein-protein interaction network involving BCL2L12 was constructed via String. Genes related to BCL2L12 in HCC were obtained from the LinkedOmics database. BCL2L12-targeted drugs for HCC were predicted via RNAactDrug, Enrichr, CTD, and NetworkAnalyst. BCL2L12 expression was upregulated and associated with poor prognosis in HCC. BCL2L12 showed significant co-occurrence with an immune checkpoint, namely TNFRSF4. BCL2L12 was significantly associated with immune infiltration in HCC. Cg03848533 methylation and CYTOR/MIR4435-2HG-has-miR-125b-5p axis regulated BCL2L12 expression and prognosis of HCC. BCL2L12 interacted with ZNF215 and PUSL1, all of which were independent risk factors for overall survival in patients with HCC. Panobinostat, Pirinixic acid, and Fluorouracil were predicted to be the potential BCL2L12-targeted drug for HCC. Our findings offer an understanding of the Oncogenic Role of BCL2L12 associated with immune status in the prognosis of HCC and provide potential strategies for currently limited treatment. - Source: PubMed
Publication date: 2025/11/26
Niu KunCao ShuangjiaoLian NanDu RuiLu Guofang